MedTrace Logo

Chinese Adults With Kidney Disease

NCT07522099 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-07-27

No results posted yet for this study

Summary

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Conditions

  • Immunoglobulin A Nephropathy (IgAN)
  • Complement 3 Glomerulopathy (C3G)
  • IC-MPGN

Interventions

DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Telitacicept

fusion protein

Sponsors & Collaborators

  • ADARx Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Arezoo Mirad · ADARx Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-21
Primary Completion
2028-07-10
Completion
2029-01-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07522099 on ClinicalTrials.gov